9684. HLA-B27/HLA-B7 (qualitative determination)

HLA stands for human major histocompatibility complex antigens, which are located on cell membranes and participate in the body's immune responses. HLA-B27 and HLA-B7 antigens are immune response markers associated with autoimmune and inflammatory diseases. HLA-B27 testing is used to differentiate arthritis, which presents with pain and asymmetrical lesions of large joints and the spine, and to predict the development of complications.

HLA-B7 is also associated with ankylosing spondylitis, but is also detected in non-autoimmune diseases. It is detected in sarcoidosis, cervical cancer (in patients with a high risk of HPV), Wegener's granulomatosis, rheumatoid arthritis, and systemic lupus erythematosus. It is recommended to administer it in combination with rheumatoid factor, C-reactive protein, and ANA testing. For patients with a high risk of HPV cancer, it is optimal to combine the test with package No. 129. This test helps identify a genetic predisposition to these diseases and optimize treatment strategies.

HLA-B27 is an antigen used to differentiate autoimmune diseases. It is detected in 90% of patients (Caucasian) with ankylosing spondylitis, sacroiliitis, and Reiter's syndrome, as well as in 60-90% of patients with reactive arthritis and 50% of patients with psoriatic arthropathy.

The HLA-B7 antigen is also associated with the risk of developing ankylosing spondylitis, but it is also detected in other non-autoimmune diseases. Monoclonal antibodies to the HLA-B7 antigen are not completely specific and can react with other antigens of the HLA-B family (primarily HLA-B7). Given this, this test uses dual antibodies to detect the HLA-B27 antigen, allowing it to differentiate between HLA-B27 and HLA-B7. This increases the specificity and sensitivity of the test. The HLA-B7 antigen, like HLA-B27, is associated with the risk of developing ankylosing spondylitis, but it is also detected in other non-autoimmune diseases (it is a risk factor for the development of cervical cancer, sarcoidosis and early onset of ankylosing spondylitis).

• Diagnosis of ankylosing spondylitis.
• Differential diagnosis of early-stage arthritis.
• Differential diagnosis in the presence of rheumatoid arthritis.
• Differential diagnosis of incomplete Reiter's syndrome (without urethritis, uveitis, or severe arthritis) and other arthritis.
• Differential diagnosis of sarcoidosis and cervical cancer.
• Prediction of a more severe course of joint syndrome in carriers of the HLA-B27 genetic marker.

• Venous blood

In order to exclude factors that may affect the test results, we recommend to follow the preparation rules: